Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Titans Of Pharma 2024

How do big pharma CEO compensation packages stack up against company performance? 

Read More

Featured Stories


Moderna Plans Big R&D Cut As Profitability Guidance Pushed Out

The biotech saw its shares plunge more than 12% after an R&D day, where it announced it would push a breakeven target from 2026 to 2028.

Business Strategies Vaccines FDA

Veozah Warning On Liver Injury Could Present New Commercial Roadblock

The US FDA updated labeling for Astellas’ drug for hot flashes after a postmarketing report of a single patient with signs and symptoms of liver injury taking the medicine. 

Women's Health Safety Risk Management

Sanofi And ITM Make Radio Waves

Two licensing deals on the same day show that radiopharmaceuticals is still an active area.

Commercial Companies Deals

Asia Spotlight

Former Hilleman CEO On Microbiome Project, Cholera, Halal Vaccine

Human milk could have a role in preventing Alzheimer’s disease and other ailments linked to the gut microbiome, says former Pfizer VP and Hilleman CEO Davinder Gill. He also talks about a halal meningitis vaccine, and tailwinds for an oral cholera vaccine now launched by Bharat Biotech in this fascinating interview



Research & Development Vaccines

More coverage from Scrip's team in Asia

Scrip Podcast

Insights and perspectives on commercial, R&D, deal-making and business strategy developments.

MORE PODCASTS

 

Scrip Originals

Executives On The Move: Five New CBOs And Three New CFOs Among This Week's Changes

Recent moves in the industry include changes at the top at LakeShore Biopharma, Atara Biotherapeutics and Defence Therapeutics, plus Transgene gets new chief medical and scientific officers.

Leadership Executive Changes

Finance Watch: Bain Capital Raises $3bn For Fourth Life Sciences Fund

Private Company Edition: Bain will invest across private and public drug, device, diagnostic and tool companies. Also, Candid debuted with $370m in initial funding, Superluminal closed a $120m series A round, PanTera raised €93m ($102.4m) in series A cash and F2G brought in $100m.

Financing Growth

Stock Watch: Regeneron Battles On Two Fronts

As it navigates product transition in ophthalmology against biosimilar and branded rivals, Regeneron seems to have a simpler challenge in another major therapeutic area.

Stock Watch Sales & Earnings

Pipeline Watch: Seven Approvals And 13 Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
Interviews

Geopolitics, US BIOSECURE: Pharma Looks To Redistribute CDMO Footprint

A redistribution of pharma outsourcing activities, both ex-China and also a wider shift in CDMO work from North America down the line may be in store. A senior McKinsey executive discusses with Scrip these trends in the CDMO sector amid geopolitical tensions, the spurt in customer queries at Indian firms and also facets of the deals scenario.

Commercial Manufacturing

Former Hilleman CEO On Microbiome Project, Cholera, Halal Vaccine

Human milk could have a role in preventing Alzheimer’s disease and other ailments linked to the gut microbiome, says former Pfizer VP and Hilleman CEO Davinder Gill. He also talks about a halal meningitis vaccine, and tailwinds for an oral cholera vaccine now launched by Bharat Biotech in this fascinating interview

Research & Development Vaccines

Hudson Holds Reins As Sanofi Makes Strides To Become R&D Powerhouse

“For 20 or 30 years, we were not seen as a scientific leader,” the French major’s CEO tells Scrip. Now, things have started to change with several positive readouts coming out of its immunology portfolio.

Leadership Business Strategies

AstraZeneca Believes Size Matters In Amyloidosis

Following the pivotal data on Alnylam’s Amvuttra, all eyes turn to the next amyloidosis readout – that of AstraZeneca and Ionis’ Wainua. And the UK major’s ambitions do not stop there.

Clinical Trials Cardiovascular
See All
Graphics

Progress Or Hype? A Decade Of Cell Therapy In Japan

After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.

Japan Policy

Obesity Rules Large-Cap Stocks In First Half Of 2024

Lilly and Novo Nordisk were top performers among large-cap pharma stocks, while the stock prices of Bristol Myers and Gilead declined the most.

Business Strategies Companies

The IPO Queue Fills Up, But A Recovery Is A Way Off

Six biopharma companies have filed to list their shares on US exchanges so far this year, but the sums they are seeking are small.

Financing Commercial

Deal Volume Up, Value Down During The First Half

Without a mega-merger like 2023’s Pfizer/Seagan takeout, M&A deals grew smaller during the first half of 2024, while volume rose. In alliance deals, H1 2024 activity somewhat mirrored activity from H1 2023.

Deals M & A
See All
Recent Stories

Aiming For Keytruda’s Crown, Summit Raises Extra Funds To Fuel Ivonescimab Ambitions

The US company believes it can not only beat Keytruda at its own game, but also achieve success where Merck & Co's blockbuster and other immunotherapies have failed.

Clinical Trials Commercial

Executives On The Move: Five New CBOs And Three New CFOs Among This Week's Changes

Recent moves in the industry include changes at the top at LakeShore Biopharma, Atara Biotherapeutics and Defence Therapeutics, plus Transgene gets new chief medical and scientific officers.

Leadership Executive Changes

Geopolitics, US BIOSECURE: Pharma Looks To Redistribute CDMO Footprint

A redistribution of pharma outsourcing activities, both ex-China and also a wider shift in CDMO work from North America down the line may be in store. A senior McKinsey executive discusses with Scrip these trends in the CDMO sector amid geopolitical tensions, the spurt in customer queries at Indian firms and also facets of the deals scenario.

Commercial Manufacturing

Finance Watch: Bain Capital Raises $3bn For Fourth Life Sciences Fund

Private Company Edition: Bain will invest across private and public drug, device, diagnostic and tool companies. Also, Candid debuted with $370m in initial funding, Superluminal closed a $120m series A round, PanTera raised €93m ($102.4m) in series A cash and F2G brought in $100m.

Financing Growth

GSK Stays In mRNA Flu Vaccine Race With Phase II Win

Its vaccine candidate will now proceed to Phase III, but might be hard pressed to compete against Moderna’s flu plus COVID-19 combination shot.

Clinical Trials Companies

Santhera Starts To Think Big After Strong Launch Of DMD Drug

The Duchenne drug Agamree has started so well in Germany and Austria that the Swiss company is expanding its self-marketing strategy in the top five European markets to include the Nordics, Portugal and Ireland.

Business Strategies Sales & Earnings

J&J’s Tremfya Gains First IBD Indication, Setting The Stage For A Big Pharma Showdown

The IL-23 inhibitor was approved by the US FDA for ulcerative colitis, joining AbbVie’s Skyrizi and Lilly’s Omvoh.

Approvals Regulation

ArriVent Targets PACC Mutation Market With EGFR TKI Firmonertinib In Lung Cancer

Newly public company ArriVent BioPharma presented Phase Ib results at WCLC for its kinase inhibitor, which could be the first drug available specifically for hard-to-treat PACC mutations.

Clinical Trials Personalized Medicine

BridgeBio Bows Out With CAH Gene Therapy Despite Trial Success

The company said the results did not meet the threshold for continued capital investment, giving a boost to Spruce Biosciences and its competing congenital adrenal hyperplasia program.

Gene Therapy Business Strategies

GSK Drops Blockbuster Hope Herpes Vaccine After Phase II Disappointment

Failure of GSK’s targeted immunotherapy leaves field open for Moderna and BioNTech candidates.

Clinical Trials Companies

Dupixent Data Could Scratch A Regulatory Itch

New pivotal data on Regeneron and Sanofi’s antibody in chronic urticaria are underwhelming, though probably sufficient for approval. A green light may beckon in bullous pemphigoid, too.

Clinical Trials Dermatology
UsernamePublicRestriction

Register